Skip to main content

Lab: Cystatin C Measurement: 2 Medicare contractor policies compared

2 Local Coverage Determinations in the current Medicare Coverage Database export carry the title "Lab: Cystatin C Measurement", between them covering 23 states and territories. 2 of them have a billing and coding article with a diagnosis list, ranging from 59 to 71 covered ICD-10-CM codes. The table below is the fastest way to see which version governs a given state and how far the versions have drifted.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Policies with this title
2
States covered
23
Versions with a coded article
2
Revision dates
2025-03-13 to 2025-09-11

Every version by contractor

Open a version for its full policy text, contracts, codes and related NCDs. Covered codes are the count of ICD-10-CM codes in the version's billing and coding article; a dash means the export attaches no coded article.

Local Coverage Determinations titled "Lab: Cystatin C Measurement"
LCDContractorStatesRevisedCovered codesPolicy words
L37581Palmetto GBAAL GA NC SC TN VA WV2025-03-1359632
L37616Noridian Healthcare Solutions, LLCAK AS AZ CA CNMI GU HI ID MT ND NV OR SD UT WA WY2025-09-1171631

Which diagnoses each contractor covers

Across the 2 versions with a coded billing and coding article, 111 ICD-10-CM codes are covered by at least one contractor: 19 by every version and 92 (83%) by only some of them. L37616 (Noridian Healthcare Solutions, LLC) covers the most codes no other version lists (52). L37581 (Palmetto GBA) leaves out the most codes that every other version covers (52), the version where a diagnosis accepted elsewhere is most often absent. The comparison is mechanical: it counts codes on the lists and does not weigh the policy text, frequency limits or documentation rules, which can matter as much as the list.

Unique codes appear on that version's covered list only; missing codes are covered by every other version but not by this one. Lists are the union of the coded billing and coding articles linked to each LCD (MCD release 2026-11-12).

Covered ICD-10-CM codes per version of Lab: Cystatin C Measurement
LCDContractorArticlesCoveredOnly hereMissing
L37581Palmetto GBAA56948594052
L37616Noridian Healthcare Solutions, LLCA57643715240

Where the lists part

Three-character ICD-10-CM categories ranked by how many of their codes are covered by some versions and not others; a category near the top is where checking the local list matters most.

ICD-10-CM categories with the most codes only some versions of Lab: Cystatin C Measurement cover
CategoryCategory title (FY2027)Codes that differ
T45Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified15
O12Gestational [pregnancy-induced] edema and proteinuria without hypertension12
T36Poisoning by, adverse effect of and underdosing of systemic antibiotics12
T52Toxic effect of organic solvents12
Q61Cystic kidney disease11
N06Isolated proteinuria with specified morphological lesion9
R80Proteinuria6
N17Acute kidney failure5
R31Hematuria5
N18Chronic kidney disease (CKD)3
R79Other abnormal findings of blood chemistry1
Z92Personal history of medical treatment1

Code-by-contractor sample

All 92 codes covered by some versions and not others, codes that most versions cover first and no more than three per category in the first pass. Y means the version's covered list includes the code.

92 of the 92 ICD-10-CM codes that only some versions of Lab: Cystatin C Measurement cover
ICD-10-CMDescription (FY2027)L37581L37616
N06.0Isolated proteinuria with minor glomerular abnormality—Y
N06.3Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis—Y
N06.4Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis—Y
N06.5Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis—Y
N06.6Isolated proteinuria with dense deposit disease—Y
N06.7Isolated proteinuria with diffuse crescentic glomerulonephritis—Y
N06.8Isolated proteinuria with other morphologic lesion—Y
N06.9Isolated proteinuria with unspecified morphologic lesion—Y
N06.AIsolated proteinuria with C3 glomerulonephritis—Y
N17.0Acute kidney failure with tubular necrosis—Y
N17.1Acute kidney failure with acute cortical necrosis—Y
N17.2Acute kidney failure with medullary necrosis—Y
N17.8Other acute kidney failure—Y
N17.9Acute kidney failure, unspecified—Y
N18.2Chronic kidney disease, stage 2 (mild)—Y
N18.4Chronic kidney disease, stage 4 (severe)—Y
N18.5Chronic kidney disease, stage 5—Y
O12.10Gestational proteinuria, unspecified trimester—Y
O12.11Gestational proteinuria, first trimester—Y
O12.12Gestational proteinuria, second trimester—Y
O12.13Gestational proteinuria, third trimester—Y
O12.14Gestational proteinuria, complicating childbirth—Y
O12.15Gestational proteinuria, complicating the puerperium—Y
O12.20Gestational edema with proteinuria, unspecified trimester—Y
O12.21Gestational edema with proteinuria, first trimester—Y
O12.22Gestational edema with proteinuria, second trimester—Y
O12.23Gestational edema with proteinuria, third trimester—Y
O12.24Gestational edema with proteinuria, complicating childbirth—Y
O12.25Gestational edema with proteinuria, complicating the puerperium—Y
Q61.00Congenital renal cyst, unspecified—Y
Q61.01Congenital single renal cyst—Y
Q61.02Congenital multiple renal cysts—Y
Q61.11Cystic dilatation of collecting ducts—Y
Q61.19Other polycystic kidney, infantile type—Y
Q61.2Polycystic kidney, adult type—Y
Q61.3Polycystic kidney, unspecified—Y
Q61.4Renal dysplasia—Y
Q61.5Medullary cystic kidney—Y
Q61.8Other cystic kidney diseases—Y
Q61.9Cystic kidney disease, unspecified—Y
R31.0Gross hematuria—Y
R31.1Benign essential microscopic hematuria—Y
R31.21Asymptomatic microscopic hematuria—Y
R31.29Other microscopic hematuria—Y
R31.9Hematuria, unspecified—Y
R79.89Other specified abnormal findings of blood chemistry—Y
R80.0Isolated proteinuria—Y
R80.1Persistent proteinuria, unspecified—Y
R80.2Orthostatic proteinuria, unspecified—Y
R80.3Bence Jones proteinuria—Y
R80.8Other proteinuria—Y
R80.9Proteinuria, unspecified—Y
T36.AX1APoisoning by fluoroquinolone antibiotics, accidental (unintentional), initial encounterY—
T36.AX1DPoisoning by fluoroquinolone antibiotics, accidental (unintentional), subsequent encounterY—
T36.AX1SPoisoning by fluoroquinolone antibiotics, accidental (unintentional), sequelaY—
T36.AX2APoisoning by fluoroquinolone antibiotics, intentional self-harm, initial encounterY—
T36.AX2DPoisoning by fluoroquinolone antibiotics, intentional self-harm, subsequent encounterY—
T36.AX2SPoisoning by fluoroquinolone antibiotics, intentional self-harm, sequelaY—
T36.AX3APoisoning by fluoroquinolone antibiotics, assault, initial encounterY—
T36.AX3DPoisoning by fluoroquinolone antibiotics, assault, subsequent encounterY—
T36.AX3SPoisoning by fluoroquinolone antibiotics, assault, sequelaY—
T36.AX4APoisoning by fluoroquinolone antibiotics, undetermined, initial encounterY—
T36.AX4DPoisoning by fluoroquinolone antibiotics, undetermined, subsequent encounterY—
T36.AX4SPoisoning by fluoroquinolone antibiotics, undetermined, sequelaY—
T45.AX1APoisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounterY—
T45.AX1DPoisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounterY—
T45.AX1SPoisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequelaY—
T45.AX2APoisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounterY—
T45.AX2DPoisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounterY—
T45.AX2SPoisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequelaY—
T45.AX3APoisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounterY—
T45.AX3DPoisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounterY—
T45.AX3SPoisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequelaY—
T45.AX4APoisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounterY—
T45.AX4DPoisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounterY—
T45.AX4SPoisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequelaY—
T45.AX5AAdverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounterY—
T45.AX5DAdverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounterY—
T45.AX5SAdverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequelaY—
T52.891AToxic effect of other organic solvents, accidental (unintentional), initial encounterY—
T52.891DToxic effect of other organic solvents, accidental (unintentional), subsequent encounterY—
T52.891SToxic effect of other organic solvents, accidental (unintentional), sequelaY—
T52.892AToxic effect of other organic solvents, intentional self-harm, initial encounterY—
T52.892DToxic effect of other organic solvents, intentional self-harm, subsequent encounterY—
T52.892SToxic effect of other organic solvents, intentional self-harm, sequelaY—
T52.893AToxic effect of other organic solvents, assault, initial encounterY—
T52.893DToxic effect of other organic solvents, assault, subsequent encounterY—
T52.893SToxic effect of other organic solvents, assault, sequelaY—
T52.894AToxic effect of other organic solvents, undetermined, initial encounterY—
T52.894DToxic effect of other organic solvents, undetermined, subsequent encounterY—
T52.894SToxic effect of other organic solvents, undetermined, sequelaY—
Z92.26Personal history of immune checkpoint inhibitor therapyY—

Download every covered code with a column per LCD (CSV). The LCD coverage variation report ranks every multi-contractor title by how far its lists diverge.

How to use the comparison

Start from the state where the service is furnished and open that contractor's version; its billing and coding article carries the diagnosis codes the claims system will test. For a group that bills in several jurisdictions, the version with the smallest covered list is the safe common denominator for pre-service review, and the version with the largest list shows what documentation can support an appeal elsewhere. The L37616 version is the one most searched for this title; the LCD lookup guide explains how jurisdictions are assigned, and the LCD hub lists every topic that more than one contractor has written.

For teams evaluating QuickIntell software

Where QuickIntell fits across jurisdictions

For teams working across MAC jurisdictions, evaluate how requirements, source policies and documentation review should be organized for each case. Confirm jurisdiction-specific scope and supported actions during a QuickAuth evaluation; compare claim and denial follow-up separately in QuickRCM.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Why are there 2 LCDs called "Lab: Cystatin C Measurement"?

Each Medicare Administrative Contractor writes its own Local Coverage Determination for its jurisdiction. 2 contractors publish a policy with this title covering 23 states; they often start from one contractor's text and then revise separately, so dates, criteria and diagnosis lists differ by jurisdiction.

Which "Lab: Cystatin C Measurement" LCD applies to my claim?

The one written by the contractor that processes the claim: the A/B MAC for the state where the service is furnished, or the DME MAC region for equipment. The table lists each policy's states; open the policy for that jurisdiction and its billing and coding article.

How different are the diagnosis lists?

Across the 2 versions with a coded billing and coding article, 111 ICD-10-CM codes are covered by at least one contractor: 19 by every version and 92 (83%) by only some of them. A diagnosis accepted under one contractor's version can deny under another's, so a group that bills in several jurisdictions checks the list of the contractor that processes each claim.

When were these policies last revised?

Revision effective dates run from 2025-03-13 to 2025-09-11. A claim is judged against the version in force on the date of service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Policy metadata and code counts are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.